Sabine Ruppel, Ph.D.

Sabine Ruppel is a results-driven drug hunter with more than 20 years of small molecule drug discovery and preclinical development experience. Previously, she served as Director and then Senior Director of Chemistry at Foghorn Therapeutics, where she spearheaded the BRD9 bi-functional degrader program. In addition to her role as Director, Sabine led the Diversity and Inclusion culture team at Foghorn. Prior to that, she served as Associate Director of Medicinal Chemistry at H3 Biomedicine. Throughout her career, Sabine has used her skills as a versatile and fast-learning leader to develop high-performing cross-functional teams and advance standout science. Sabine also has previous experience as a Principal Scientist at FORMA Therapeutics and Boehringer Ingelheim, where she honed her strategic skills and harnessed her creativity to solve multidimensional challenges. She holds a Ph.D. in Physical and Theoretical Chemistry from the University of California, Davis and completed postdoctoral research at Berlex Biosciences and Sandia National Laboratories in California.